Haemorrhage prophylaxis focuses on preventing severe and potentially life-threatening blood loss before it occurs, particularly in situations where bleeding is a known risk. This protective approach plays a critical role in maternal health, surgical procedures, and the care of people with bleeding disorders, helping to reduce complications and save lives.

Understanding How Prevention Protects Against Dangerous Bleeding

Preventing excessive blood loss before it starts is a cornerstone of modern medical care. Haemorrhage prophylaxis refers to the use of medications, strategies, and clinical approaches designed to stop dangerous bleeding before it develops or becomes severe. This is especially important in childbirth, where sudden and heavy bleeding can quickly become life-threatening, as well as in people with inherited bleeding disorders who are at constant risk of internal or external bleeding episodes.^[1]

The goal of prophylaxis is not just to reduce the amount of blood lost, but to prevent the cascade of complications that follow severe bleeding. When someone loses a large amount of blood rapidly, their blood pressure drops, organs may not receive enough oxygen, and the body’s normal clotting system can fail. By stepping in early with preventive treatments, healthcare providers can avoid these dangerous situations entirely or minimize their impact.^[2]

Prophylactic strategies vary depending on the clinical situation. In obstetrics, prevention focuses on the moments immediately after delivery when the risk of bleeding is highest. In people with rare bleeding disorders, prophylaxis may involve regular infusions of clotting factors to maintain a baseline level of protection. In surgical settings, doctors may use medications that strengthen clotting or reduce the breakdown of blood clots during and after procedures where bleeding risk is elevated.^[4]

Standard Approaches to Preventing Postpartum Hemorrhage

One of the most studied and effective forms of haemorrhage prophylaxis occurs during childbirth. Postpartum hemorrhage, defined as blood loss of 1,000 mL or more with signs of low blood volume within 24 hours after delivery, is a leading cause of maternal death worldwide. It accounts for approximately 12% of maternal deaths in the United States and one-fourth of maternal deaths globally.^[1][6]

The most important preventive measure is called active management of the third stage of labor. This refers to the time between delivery of the baby and delivery of the placenta. Active management involves giving the mother a medication called oxytocin right after the baby’s anterior shoulder is delivered, along with controlled pulling on the umbilical cord to help deliver the placenta. This approach reduces the risk of postpartum hemorrhage by 68% compared to waiting for the placenta to come out on its own.^[5][12]

Oxytocin is the first-choice drug for prevention because it causes the uterus, the muscular organ that holds the baby during pregnancy, to contract strongly. After the baby is born, the placenta detaches from the wall of the uterus, leaving open blood vessels behind. Strong uterine contractions squeeze these blood vessels shut, much like clamping a hose, and this stops the bleeding. Oxytocin works quickly, has fewer side effects than other options, and is more effective at preventing uterine atony, which is when the uterus fails to contract properly and is responsible for up to 80% of postpartum bleeding cases.^[1][3]

Other medications can be used if oxytocin is not available or not effective. Misoprostol, a type of medication called a prostaglandin, can be given by mouth or placed inside the cheek to help the uterus contract. However, it causes more side effects such as shivering, fever, and nausea compared to oxytocin. Ergot alkaloids, another group of drugs, also cause uterine contractions but can raise blood pressure and are not safe for all women.^[5][12]

Avoiding unnecessary procedures also plays a role in prevention. For example, routine episiotomy, which is a cut made in the tissue between the vagina and anus to widen the birth opening, actually increases blood loss and the risk of severe tearing. It should only be done when urgently needed.^[1]

Healthcare systems are encouraged to have hemorrhage prevention protocols in place at every delivery unit. This includes having a “hemorrhage cart” stocked with medications, supplies, checklists, and clear instructions so that staff can act quickly. Hospitals also benefit from forming response teams and holding regular training sessions with realistic simulations to improve coordination and response time.^[1][8]

Tranexamic Acid: A Key Medication for Bleeding Prophylaxis

Tranexamic acid is a medication that has become increasingly important in preventing and treating hemorrhage across many medical situations. It is a synthetic drug that works by blocking the breakdown of blood clots. Normally, the body has a system called fibrinolysis that dissolves clots once healing is complete. In some cases, this system becomes overactive, a condition called hyperfibrinolysis, and clots dissolve too quickly, leading to uncontrolled bleeding. Tranexamic acid slows this process down, helping clots stay in place longer and giving the body time to heal.^[4][9]

Tranexamic acid has been available since 1966 and is now considered essential by the World Health Organization. It is used in trauma patients, during surgeries on organs rich in clotting activators such as the liver, kidney, pancreas, uterus, and prostate, and in postpartum hemorrhage. Studies have shown that it reduces the need for blood transfusions and lowers blood loss during procedures.^[4][11]

In postpartum hemorrhage, tranexamic acid given within the first three hours after birth reduces the number of deaths caused by bleeding, although it does not reduce overall mortality from all causes. Timing is critical—if given too late, it may not be as effective or could even cause harm. The drug is particularly useful when oxytocin and other first-line treatments are not enough to control bleeding.^[1][8]

Tranexamic acid has been shown to reduce bleeding in many types of surgery, including cesarean section, heart surgery, orthopedic surgery, and dental extractions in people taking blood thinners. It has moderate evidence for effectiveness in procedures like tonsillectomy, liver surgery, and treatment of nosebleeds. However, it was not found to be effective in traumatic brain injury or gastrointestinal bleeding.^[11]

Like all medications, tranexamic acid has potential side effects. At high doses or in certain situations, such as brain injury or heart surgery, it has been associated with an increased risk of seizures. Some studies have also raised concerns about a possible increase in blood clots in the legs or lungs, particularly in trauma and gastrointestinal bleeding, though most trials did not find this risk.^[11]

Prophylaxis in Rare Bleeding Disorders

People with rare inherited bleeding disorders, such as deficiencies in specific clotting factors, face a lifelong risk of spontaneous bleeding into joints, muscles, and organs. In these individuals, prophylactic treatment means regularly infusing the missing clotting factor into the bloodstream to maintain a protective level, rather than waiting until bleeding occurs.^[10]

Rare bleeding disorders include deficiencies in fibrinogen, prothrombin, and factors II, V, VII, X, XI, and XIII, as well as deficiencies in proteins that control clot breakdown like alpha-2-antiplasmin. The frequency and severity of bleeding vary depending on which clotting factor is missing and how much residual activity remains. Symptoms can range from minor issues like frequent nosebleeds to life-threatening events like bleeding in the brain.^[10]

For people with severe forms of these disorders, prophylactic infusions can prevent joint damage, reduce the number of bleeding episodes, and improve quality of life. The challenge is that replacement products for rare clotting factors are not always available, and treatment must be individualized based on the specific deficiency and bleeding pattern.^[10]

In addition to clotting factor replacement, some patients benefit from antifibrinolytic drugs like tranexamic acid, which can be taken by mouth regularly to reduce minor bleeding such as heavy menstrual periods or nosebleeds. This is especially useful in disorders where excessive clot breakdown is part of the problem.^[4]

Innovative Research and Clinical Trials in Hemorrhage Prevention

Research into better ways to prevent hemorrhage continues in multiple areas. In postpartum care, the World Health Organization has published consolidated guidelines that bring together evidence-based interventions for the prevention, diagnosis, and treatment of postpartum hemorrhage. These guidelines aim to standardize care globally and improve implementation of life-saving measures, especially in low-resource settings where maternal mortality from bleeding remains high.^[14]

Clinical trials are exploring optimal dosing and timing of medications like oxytocin and tranexamic acid. For example, researchers are studying whether giving tranexamic acid immediately after delivery to all women, not just those already bleeding, could further reduce mortality. Other studies are looking at whether combining multiple preventive medications offers better protection than using one drug alone.^[18]

In trauma care, the use of massive transfusion protocols—standardized approaches to rapidly replacing blood and clotting factors in patients with severe bleeding—has become standard in many hospitals. These protocols help prevent a dangerous complication called dilutional coagulopathy, where giving too much intravenous fluid without replacing clotting factors causes the remaining blood to clot poorly.^[1][8]

For people with rare bleeding disorders, ongoing clinical trials are testing new clotting factor products, including longer-acting versions that require less frequent infusions, and exploring gene therapy approaches that could potentially cure these conditions by correcting the underlying genetic defect.^[10]

Systems-Level Strategies for Better Outcomes

Preventing hemorrhage requires more than just medications—it requires well-coordinated systems of care. The National Partnership for Maternal Safety has developed an obstetric hemorrhage consensus bundle with 13 recommendations at both patient and system levels. These include readiness measures like having hemorrhage carts available, recognition measures like accurate blood loss assessment, response protocols with clear team roles, and reporting systems to learn from every hemorrhage event.^[1]

Team training with realistic simulation has been shown to improve outcomes. When doctors, nurses, and other staff practice responding to hemorrhage scenarios together, they learn to communicate more effectively, make decisions faster, and work as a coordinated unit when real emergencies occur.^[1]

Accurate measurement of blood loss is also crucial but challenging. Visual estimation often underestimates actual blood loss, which can delay treatment. Many hospitals now use quantitative blood loss measurement, which involves weighing blood-soaked materials or using collection devices that measure volume precisely. This helps identify hemorrhage earlier when interventions are most effective.^[2]

For women at high risk of hemorrhage—such as those with placental abnormalities, multiple pregnancies, or a history of previous hemorrhage—planning delivery at a facility with immediately available surgical services, intensive care, and blood bank support can be life-saving.^[1]

Most common treatment methods

• Active management of the third stage of labor
  • Administration of oxytocin immediately after delivery of the baby’s anterior shoulder
  • Controlled traction on the umbilical cord to deliver the placenta
  • Early cord clamping and cutting
  • Reduces postpartum hemorrhage risk by 68% compared to expectant management
• Uterotonic medications
  • Oxytocin: First-line drug for preventing and treating uterine atony, with fewer side effects
  • Misoprostol: Prostaglandin used when oxytocin is unavailable, causes more side effects
  • Ergot alkaloids: Cause uterine contractions but can raise blood pressure
• Antifibrinolytic therapy
  • Tranexamic acid given within three hours of birth reduces mortality from bleeding
  • Blocks breakdown of blood clots by inhibiting fibrinolysis
  • Used in surgery, trauma, and rare bleeding disorders
  • Reduces need for blood transfusions in multiple clinical settings
• Clotting factor replacement
  • Regular prophylactic infusions for people with rare bleeding disorders
  • Maintains baseline level of missing clotting factors
  • Prevents spontaneous bleeding into joints, muscles, and organs
  • Treatment individualized based on specific factor deficiency
• Massive transfusion protocols
  • Standardized approach to rapidly replace blood and clotting factors
  • Used when blood loss exceeds 1,500 mL
  • Prevents dilutional coagulopathy
  • Requires coordination between healthcare team and blood bank